Cargando…

Bioreactor-grown exo- and endo-β-glucan from Malaysian Ganoderma lucidum: An in vitro and in vivo study for potential antidiabetic treatment

This study aims to identify the roles of exo-β-glucan (EPS-BG) and endo-β-glucan (ENS-BG) extracted from Ganoderma lucidum (GL) in inhibiting the alpha-glucosidase enzyme, a target mechanism for postprandial hyperglycaemia regulation. Upscale production of GL was carried out using a 10 L bioreactor....

Descripción completa

Detalles Bibliográficos
Autores principales: Abdullah, Nur Raihan, Mohd Nasir, Mohd Hamzah, Azizan, Nur Hafizah, Wan-Mohtar, Wan Abd Al Qadr Imad, Sharif, Faez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452895/
https://www.ncbi.nlm.nih.gov/pubmed/36091430
http://dx.doi.org/10.3389/fbioe.2022.960320
_version_ 1784785018257670144
author Abdullah, Nur Raihan
Mohd Nasir, Mohd Hamzah
Azizan, Nur Hafizah
Wan-Mohtar, Wan Abd Al Qadr Imad
Sharif, Faez
author_facet Abdullah, Nur Raihan
Mohd Nasir, Mohd Hamzah
Azizan, Nur Hafizah
Wan-Mohtar, Wan Abd Al Qadr Imad
Sharif, Faez
author_sort Abdullah, Nur Raihan
collection PubMed
description This study aims to identify the roles of exo-β-glucan (EPS-BG) and endo-β-glucan (ENS-BG) extracted from Ganoderma lucidum (GL) in inhibiting the alpha-glucosidase enzyme, a target mechanism for postprandial hyperglycaemia regulation. Upscale production of GL was carried out using a 10 L bioreactor. The zebrafish embryo toxicity test (ZFET) was carried out based on OECD guidelines. The hatching rate, survival rate, heart rate, morphological malformation, and teratogenic defects were observed and determined every 24 h from 0–120 h of post-exposure (hpe). For diabetes induction, adult zebrafish (3–4 months of age) were overfed and induced with three doses of 350 mg/kg streptozotocin (STZ) by intraperitoneal injection (IP) on three different days (days 1, 3, and 5). The oral sucrose tolerance test (OSTT) and anti-diabetic activity of EPS-BG and ENS-BG were evaluated (day 7) using the developed model (n = 15). This study showed that EPS is the most potent compound with the highest inhibitory effect toward the alpha-glucosidase enzyme with an IC(50) value of 0.1575 mg/ml compared to ENS extracts (IC(50) = 0.3479 mg/ml). Both EPS-BG and ENS-BG demonstrated a strong inhibition of alpha-glucosidase activity similar to the clinically approved alpha-glucosidase inhibitor, acarbose (IC(50) = 0.8107 mg/ml). ENS-BG is non-toxic toward zebrafish embryos with LC(50) of 0.92 mg/ml and showed no significant changes in ZE hatching and normal heart rate as compared to untreated embryos (161 beats/min). Teratogenic effects of ENS-BG (<1.0 mg/ml) on zebrafish embryonic development were not observed. The DM model of zebrafish was acquired after the third dose of STZ with a fasting BGL of 8.98 ± 0.28 mmol/L compared to the normal healthy group (4.23 ± 0.62 mmol/L). The BGL of DM zebrafish after 30 min treated with EPS-BG and ENS-BG showed a significant reduction (p < 0.0001). Both EPS-BG and ENS-BG significantly reduced DM zebrafish’s peak blood glucose and the area under the curve (AUC) in OSTT. Hence, EPS-BG and ENS-BG extracted from GL showed promising inhibition of the alpha-glucosidase enzyme and are considered non-toxic in ZE. Moreover, EPS-BG and ENS-BG reduced blood glucose levels and inhibited hyperglycemia in DM zebrafish.
format Online
Article
Text
id pubmed-9452895
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94528952022-09-09 Bioreactor-grown exo- and endo-β-glucan from Malaysian Ganoderma lucidum: An in vitro and in vivo study for potential antidiabetic treatment Abdullah, Nur Raihan Mohd Nasir, Mohd Hamzah Azizan, Nur Hafizah Wan-Mohtar, Wan Abd Al Qadr Imad Sharif, Faez Front Bioeng Biotechnol Bioengineering and Biotechnology This study aims to identify the roles of exo-β-glucan (EPS-BG) and endo-β-glucan (ENS-BG) extracted from Ganoderma lucidum (GL) in inhibiting the alpha-glucosidase enzyme, a target mechanism for postprandial hyperglycaemia regulation. Upscale production of GL was carried out using a 10 L bioreactor. The zebrafish embryo toxicity test (ZFET) was carried out based on OECD guidelines. The hatching rate, survival rate, heart rate, morphological malformation, and teratogenic defects were observed and determined every 24 h from 0–120 h of post-exposure (hpe). For diabetes induction, adult zebrafish (3–4 months of age) were overfed and induced with three doses of 350 mg/kg streptozotocin (STZ) by intraperitoneal injection (IP) on three different days (days 1, 3, and 5). The oral sucrose tolerance test (OSTT) and anti-diabetic activity of EPS-BG and ENS-BG were evaluated (day 7) using the developed model (n = 15). This study showed that EPS is the most potent compound with the highest inhibitory effect toward the alpha-glucosidase enzyme with an IC(50) value of 0.1575 mg/ml compared to ENS extracts (IC(50) = 0.3479 mg/ml). Both EPS-BG and ENS-BG demonstrated a strong inhibition of alpha-glucosidase activity similar to the clinically approved alpha-glucosidase inhibitor, acarbose (IC(50) = 0.8107 mg/ml). ENS-BG is non-toxic toward zebrafish embryos with LC(50) of 0.92 mg/ml and showed no significant changes in ZE hatching and normal heart rate as compared to untreated embryos (161 beats/min). Teratogenic effects of ENS-BG (<1.0 mg/ml) on zebrafish embryonic development were not observed. The DM model of zebrafish was acquired after the third dose of STZ with a fasting BGL of 8.98 ± 0.28 mmol/L compared to the normal healthy group (4.23 ± 0.62 mmol/L). The BGL of DM zebrafish after 30 min treated with EPS-BG and ENS-BG showed a significant reduction (p < 0.0001). Both EPS-BG and ENS-BG significantly reduced DM zebrafish’s peak blood glucose and the area under the curve (AUC) in OSTT. Hence, EPS-BG and ENS-BG extracted from GL showed promising inhibition of the alpha-glucosidase enzyme and are considered non-toxic in ZE. Moreover, EPS-BG and ENS-BG reduced blood glucose levels and inhibited hyperglycemia in DM zebrafish. Frontiers Media S.A. 2022-08-25 /pmc/articles/PMC9452895/ /pubmed/36091430 http://dx.doi.org/10.3389/fbioe.2022.960320 Text en Copyright © 2022 Abdullah, Mohd Nasir, Azizan, Wan-Mohtar and Sharif. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Abdullah, Nur Raihan
Mohd Nasir, Mohd Hamzah
Azizan, Nur Hafizah
Wan-Mohtar, Wan Abd Al Qadr Imad
Sharif, Faez
Bioreactor-grown exo- and endo-β-glucan from Malaysian Ganoderma lucidum: An in vitro and in vivo study for potential antidiabetic treatment
title Bioreactor-grown exo- and endo-β-glucan from Malaysian Ganoderma lucidum: An in vitro and in vivo study for potential antidiabetic treatment
title_full Bioreactor-grown exo- and endo-β-glucan from Malaysian Ganoderma lucidum: An in vitro and in vivo study for potential antidiabetic treatment
title_fullStr Bioreactor-grown exo- and endo-β-glucan from Malaysian Ganoderma lucidum: An in vitro and in vivo study for potential antidiabetic treatment
title_full_unstemmed Bioreactor-grown exo- and endo-β-glucan from Malaysian Ganoderma lucidum: An in vitro and in vivo study for potential antidiabetic treatment
title_short Bioreactor-grown exo- and endo-β-glucan from Malaysian Ganoderma lucidum: An in vitro and in vivo study for potential antidiabetic treatment
title_sort bioreactor-grown exo- and endo-β-glucan from malaysian ganoderma lucidum: an in vitro and in vivo study for potential antidiabetic treatment
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452895/
https://www.ncbi.nlm.nih.gov/pubmed/36091430
http://dx.doi.org/10.3389/fbioe.2022.960320
work_keys_str_mv AT abdullahnurraihan bioreactorgrownexoandendobglucanfrommalaysianganodermalucidumaninvitroandinvivostudyforpotentialantidiabetictreatment
AT mohdnasirmohdhamzah bioreactorgrownexoandendobglucanfrommalaysianganodermalucidumaninvitroandinvivostudyforpotentialantidiabetictreatment
AT azizannurhafizah bioreactorgrownexoandendobglucanfrommalaysianganodermalucidumaninvitroandinvivostudyforpotentialantidiabetictreatment
AT wanmohtarwanabdalqadrimad bioreactorgrownexoandendobglucanfrommalaysianganodermalucidumaninvitroandinvivostudyforpotentialantidiabetictreatment
AT shariffaez bioreactorgrownexoandendobglucanfrommalaysianganodermalucidumaninvitroandinvivostudyforpotentialantidiabetictreatment